Affibody Enter Into An Option Agreement Regarding IL-17-Targeting Molecules In Ophthalmology

Solna, Sweden, April 12, 2016 – Affibody AB (“Affibody”) today announced that the company has signed a Research License and Product Option Agreement with an unnamed partner.

The agreement relates to the therapeutic use of Affibody’s proprietary IL-17 targeting Affibody® molecules in ophthalmology indications.

Further details of the agreement have not been disclosed.

Back to news